Conformationally constrained backbone cyclized peptide analogs

Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Cyclic peptides

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S333000, C530S324000, C514S002600

Reexamination Certificate

active

07084244

ABSTRACT:
Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are Nα(ω-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these Nα(ω-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

REFERENCES:
patent: 3988304 (1976-10-01), Garsky
patent: 4011182 (1977-03-01), Sarantakis
patent: 4054558 (1977-10-01), Garsky
patent: 4187217 (1980-02-01), Chipens et al.
patent: 4191754 (1980-03-01), Veber et al.
patent: 4235886 (1980-11-01), Freidinger et al.
patent: 4290943 (1981-09-01), Birr
patent: 4310518 (1982-01-01), Freidinger et al.
patent: 5364851 (1994-11-01), Joran
patent: 5371070 (1994-12-01), Koerber et al.
patent: 5811392 (1998-09-01), Gilon et al.
patent: 6051554 (2000-04-01), Hornik et al.
patent: 6117974 (2000-09-01), Gilon et al.
patent: 6841533 (2005-01-01), Hornik et al.
patent: 41 19 544 (1992-10-01), None
patent: 0 334 244 (1989-09-01), None
patent: 0 336 779 (1989-10-01), None
patent: 0 370 453 (1990-05-01), None
patent: 0 336 779 (1991-08-01), None
patent: 0 564 739 (1993-10-01), None
patent: 0 564 739 (1995-04-01), None
patent: 2304352 (1976-10-01), None
patent: 2411828 (1979-07-01), None
patent: WO 89/01781 (1989-03-01), None
patent: WO 92/00091 (1992-01-01), None
patent: WO 92/22566 (1992-12-01), None
patent: WO 93/01206 (1993-01-01), None
patent: WO 94/11393 (1994-05-01), None
Bell et al., 1993, “Molecular biology of somatostatin receptors”, TINS, vol. 16, No. 1, 34-38.
Brazeau et al, 1973, “Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreative Pituitary Growth Hormone”, SCIENCE, vol. 179, pp. 77-79.
Buscail et al., 1995, “Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms”,Proc. Natl. Acad. Sci. USA92:1580-1584.
Byk et al., 1992, “Building units for N-backbone cyclic peptides. 1. Synthesis of protected N-(ω-aminoalkylene)amino acids and their incorporation into dipeptide units”,J. Org. Chem.57:5687-5692.
Charpentier et al., 1989, “Synthesis and Binding Affinities of Cyclic and Related Linear Analogues of CCK8Selective for Central Receptors”,J. Med. Chem., pp. 1184-1190.
Giannis et al., 1993, “Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Perspectives”,Angew. Chem. Int. Ed. Engl. 32:1244-1267.
Gilon et al., 1991, “Backbone Cyclization: A New Method for Conferring Conformational Constraint on Peptides”,Biopolymers31:745-750.
Gilon et al., 1992, “SAR studies of cycloseptide: Effects of cyclization and charge at position6”,Chem. Biol.Proc Am Pept Symp 1th. pp. 476-477.
Greiner et al., 1994, “Synthesis of New Backbone-Cyclized Bradykinin Analogs”,Proc. Eur. Pept. Symp., 23rd, Meeting Date 1994, 289-290.
Hruby et al., 1990, “Emerging approaches in the molecfular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations”,Biochem J. 268:249-262.
Krstenansky et al., 1994, “Cyclic hexapeptide antagonists of the bradykinin B2receptor: Receptor binding and solution backbone conformation”,Letters in Peptide Science1:229-234.
Lamberts, 1998, “The Role of Somatostatin in the Regulation of Anterior Pituitary Hormone Secretion and the Use of Its Analogs in the Treatment of Human Pituitary Tumors”,Endocrine Reviewsvol. 9, No. 4, pp. 417-436.
Lamberts et al., 1990, “Somatostatin-receptor imaging in the localization of endocrine tumors”,New England J. Med. 323:1246-1249.
Lymangrover et al., 1993, “Varying the Duration of A23187 Administration Alters its Effect on Adrenal Steroidogenesis”,Life Sciences34:371-377.
Mosberg et al., 1983, “Bis-penicillamine enkephalins possess highly improved specificity toward σ0 opioid receptors”,Biochemistry80:5871-5874.
Plotsky et al., 1985, “Patterns of growth hormone-releasing factor and comatostatin secretion into the hypophysial-portal circulation of the rat”,Science230:461-463.
Reynor et al., 1993, “Cloned somatostatin receptors: Identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides”,Mol. Pharmacol.43:838-844.
Reisine et al., 1995, “Molecular biology of somatostatin receptors”,Endocrine Reviews16:427-442.
Reubi et al., 1995, “Multiple actions of somatostatin in neoplastic disease,”TIPS16:110-115.
Rizo et al., 1992, “Constrained Peptides: Models of Bioactive Peptides and Protein Substructures”,Annu. Rev. Biochem. 61:387-418.
Rodriguez et al., 1980, “Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors”,Int. J. Peptide Protein Res. 35:441-451.
Steranka et al., 1988, “Bradykinin as a pain mediator: Receptors are localized to sensory neurons, and antagonists have analgesic actions”,Proc. Natl. Acad. Sci. USA85:3245-3249.
Verber et al., 1984, “A super active cyclic hexapeptide analog of somatostatin”,Life Sciences34:1371-1378.
Veber et al., 1985, “The design of metabolically-stable peptide analogs”,TINS, pp. 392-396.
Zuckerman, 1993, “The chemical synthesis of peptidomimetic libraries”,Current Opinion in Structural Biol. 3:580-584.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Conformationally constrained backbone cyclized peptide analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Conformationally constrained backbone cyclized peptide analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conformationally constrained backbone cyclized peptide analogs will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3716163

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.